Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI134213-01
Agency Tracking Number: R41AI134213
Amount: $117,817.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-08-01
Award End Date (Contract End Date): 2018-05-31
Small Business Information
1928 SW 36TH PL, Gainesville, FL, 32608-3436
DUNS: 004095863
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 GREGORY MARSHALL
 (352) 871-4074
 gregory.marshall@sfcollege.edu
Business Contact
 TODD BRUSKO
Phone: (352) 273-9255
Email: tbrusko@ufl.edu
Research Institution
 UNIVERSITY OF FLORIDA
 219 Grinter Hall
GAINESVILLE, FL, 32611-5500
 Nonprofit college or university
Abstract
Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patients diagnosed annually resulting in roughly $ B in health care costs in the US each year It is thought that arrest of the autoimmune processes underlying this disease could avert the long term complications associated with the disease and perhaps even reverse the disease process given sufficient insulin producing cells remain Clinical intervention trials using immunomodulatory agents e g anti CD have failed to meet clinical endpoints despite positive results in phase I II trials and traditional vaccine strategies providing auto antigen or peptides alone failed to adequately block ongoing beta cell immunity Thus a new treatment strategy that is both potent and durable is required to effectively halt the ongoing attack in T D The immune system utilizes two important strategies to prevent the aberrant targeting and destruction of self tissues the production of regulatory T cells Tregs and the limitation of inflammatory responses to prevent collateral damage Recent studies have revealed that the intracellular protein suppressor of cytokine signaling SOCS plays a crucial role in regulating immune responses and in the survival and phenotypic stability of regulatory T cells and that defects in its production and availability plays a critical role in the manifestation of a variety of auto immune diseases Despite its obvious appeal as a potential therapy enthusiasm has been dampened due to the extremely limited stability of therapeutically administered SOCS in its pure form We have managed to synthetically manufacture small peptide SOCS mimetics that possess the functional capacity of SOCS allowing for cost and time efficient production of this potential therapeutic The objective of this Phase I proposal is to establish the feasibility of utilizing our small peptide SOCS mimetics at varying doses to prevent the onset of T D in an animal model of the disease The results from these studies will allow us to proceed to Phase II of the SBIR in which studies will be conducted to satisfy the FDA requirements for the production of a clinical grade drug suitable for Human Phase I II clinical trials as a novel therapy for T D Our long term goal is to develop an easily injectable therapy capable of prevention and reversal of a wide variety of auto immune diseases greatly enhancing the potential for widespread use Our preliminary data strongly suggests that this therapy holds promise for correcting autoimmune responses in T D Additionally our strategic collaborations with the Diabetes Center of Excellence at the University of Florida bolster our ability to complete the desired goals Type diabetes T D is an autoimmune disease that carries a personal health burden that extends to a tremendous socioeconomic impact in the US and therapeutic approaches for T D focusing on restoring immune tolerance mechanisms hold huge promise to correct the autoimmune response We seek to combat the underlying autoimmune processes that drive T D by administering suppressor of cytokine signaling peptide mimetics designed to inhibit inflammatory cytokine responses and enhance regulatory T cell function thereby restoring immune tolerance in a stable and robust manner

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government